This site is intended for Healthcare Professionals only.

Batches of Latuda tablets by CNX Therapeutics to arrive without barcodes

Date:

Share post:

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for Latuda film-coated tablets by CNX Therapeutics.

CNX Therapeutics have notified the MHRA that a few batches of Latuda film-coated tablets will be released without EAN barcodes on the cartons. The batch numbers and the expiry dates are present and clearly visible on the cartons and on the blisters.

Although fully in line with the Marketing Authorisation, the absence of the barcodes may lead to queries as these may sometimes be used for stock control and automated dispensing.

This stock has not yet been distributed, however due to the consideration for stock control and automated dispensing, this notification is being shared in advance of distribution from CNX Therapeutics to wholesalers and pharmacies. The expected distribution dates for these batches will take place between April 2022 and July 2022.

Product description

Latuda 18.5mg film-coated tablets PLGB 19635/00035

Batch Number Expiry Date Pack Size First Distributed
0011 30 August 2025 28 Not Yet Distributed
0013 31 December 2025 28 Not Yet Distributed

 

Latuda 37mg film-coated tablets PLGB 19635/0004

Batch Number Expiry Date Pack Size First Distributed
0020 30 November 2025 28 Not Yet Distributed
0021 30 November 2025 28 Not Yet Distributed

 

Latuda 74 mg film-coated tablets PLGB 19635/0005

Batch Number Expiry Date Pack Size First Distributed
0029 31 December 2025 28 Not Yet Distributed
0030 31 December 2025 28 Not Yet Distributed
0031 31 March 2025 28 Not Yet Distributed

Active Pharmaceutical Ingredient: Lurasidone (as lurasidone hydrochloride)

Wholesalers and healthcare professionals are urged to refer to the batch number and expiry date printed on the carton for stock control and dispensing. The impacted products are within specification and there is no issue with product quality and are not being recalled.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

MHRA outlines strategic approach to AI regulation in healthcare for patient safety

MHRA's strategic principles aim to foster innovation while upholding rigorous standards of patient safety and regulatory integrity In a...

CCA report highlights success: 90,000 pharmacy first consultations since launch

The pharmacy first report reveals impressive uptake and patient satisfaction in just two months In a recent report released...

RPS and Pharmacy Support join hands for pharmacy professionals wellbeing

Marks a significant milestone in the pharmacy sector's commitment to nurturing its pharmacy family The Royal Pharmaceutical Society (RPS)...

Atulkumar Patel: A beacon of resilience and innovation in pharmacy practice

Despite offers to join full-time in a GP practice, Patel chose to remain dedicated to his community, becoming...